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Abstract
Objective: ATL1103 is a second-generation antisense oligomer targeting the human growth hormone (GH) receptor. This 
phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly.
Design: Twenty-six patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous 
ATL1103 200 mg either once or twice weekly for 13 weeks and monitored for a further 8-week washout period.
Methods: The primary eficacy measures were change in IGF-I at week 14, compared to baseline and between cohorts. 
For secondary endpoints (IGFBP3, acid labile subunit (ALS), GH, growth hormone-binding protein (GHBP)), comparison 
was between baseline and week 14. Safety was assessed by reported adverse events.
Results and conclusions: Baseline median IGF-I was 447 and 649 ng/mL in the once- and twice-weekly groups 
respectively. Compared to baseline, at week 14, twice-weekly ATL1103 resulted in a median fall in IGF-I of 27.8% 
(P = 0.0002). Between cohort comparison at week 14 demonstrated the median fall in IGF-I to be 25.8% (P = 0.0012) 
greater with twice-weekly dosing. In the twice-weekly cohort, IGF-I was still declining at week 14, and remained 
lower at week 21 than at baseline by a median of 18.7% (P = 0.0005). Compared to baseline, by week 14, IGFBP3 and 
ALS had declined by a median of 8.9% (P = 0.027) and 16.7% (P = 0.017) with twice-weekly ATL1103; GH had increased 
by a median of 46% at week 14 (P = 0.001). IGFBP3, ALS and GH did not change with weekly ATL1103. GHBP fell by a 
median of 23.6% and 48.8% in the once- and twice-weekly cohorts (P = 0.027 and P = 0.005) respectively. ATL1103 was 
well tolerated, although 84.6% of patients experienced mild-to-moderate injection-site reactions. This study provides 
proof of concept that ATL1103 is able to signiicantly lower IGF-I in patients with acromegaly.
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Introduction
Acromegaly is a rare, chronic, life-shortening disease 
caused by hypersecretion of growth hormone (GH), 
virtually always due to a pituitary adenoma, that in turn 
results in elevated circulating levels of insulin-like growth 
factor 1 (IGF-I) (1). Conventional therapy is directed at 
the pituitary gland and attempts to reduce GH secretion 
by means of surgery, radiotherapy or medical therapy 
in the form of somatostatin analogues and dopamine 
agonists (2). The GH receptor antagonist pegvisomant has 
successfully exploited an alternative therapeutic approach, 
namely to block GH action rather than secretion (3).
Antisense oligonucleotides (ASOs) are single-stranded 
synthetic oligonucleotides that have been developed as 
therapeutic agents. Translation of mRNA, and hence, protein 
synthesis, is inhibited by sequence-speciic ASOs that bind 
target pre-mRNA and/or mRNA (4). In the early 1990s, 
clinical trials with ASOs began, and in 1998, fomivirsen 
became the irst oligonucleotide to be approved by the US 
Food and Drug Administration (FDA) for the treatment of 
cytomegalovirus retinitis (5). In 2013, the second-generation 
ASO inhibitor mipomersen was approved by the FDA for the 
treatment of homozygous familial hypercholesterolaemia. 
Currently, there are more than 30 second-generation ASOs, 
including ATL1103, in clinical development for a variety 
of neurological, oncological, cardiovascular and metabolic 
conditions. Excellent reviews of the technology are available 
elsewhere (6).
ATL1103 is a second-generation, antisense oligomer 
designed to inhibit translation of human growth 
hormone receptor (GHR) mRNA (Fig.  1). It comprises 
20 nucleotides with a phosphorothioate backbone and 
2′-O-methoxyethyl modiications of the terminal ive 
nucleotides at each end, which in combination increase 
its plasma half-life and afinity for the mRNA. Post-
hybridisation RNase H degradation results in inhibition 
of GHR translation. In pre-clinical rodent and primate 
studies, ATL1103 reduced GHR mRNA levels in the liver 
and serum IGF-I, with a terminal half-life of 2–4 weeks (7). 
Phase 1 studies in healthy male volunteers demonstrated a 
fall in serum IGF-I and growth hormone–binding protein 
(GHBP) (https://www.asx.com.au/asxpdf/20111207/pdf/ 
4234016x2cj5xn.pdf).
The objectives of this study were to evaluate the 
safety, tolerability and eficacy of ATL1103 in patients 
with acromegaly. Serum IGF-I was the primary measure 
of eficacy, with the other components of the IGF ternary 
complex, namely IGF-binding protein 3 (IGFBP3) and 
acid labile subunit (ALS) being additional measures of 
disease activity. Circulating GH and GHBP, the cleaved 
extracellular component of the GHR, were monitored to 
provide insight into the physiological implications of an 
ASO targeting the GHR. For the primary eficacy variable, 
the null hypothesis of no percentage change in fasting 
IGF-I levels from baseline to week 14 was tested for each 
treatment regimen.
Subjects and methods
Study design
This was a phase 2 randomised, open-label, parallel-group 
study of the safety, tolerability, pharmacokinetics and 
eficacy of two subcutaneous dosing regimens of ATL1103 
in patients with acromegaly (Fig. 2).
Exclusion/inclusion criteria
Inclusion criteria
Patients who
1. provided written informed consent in accordance 
with local regulations,
20-mer phosphorothioate backbone
2´ -deoxy “gap” (DNA)
10
“2´ -MOE” (RNA)
5
“2´ -MOE” (RNA)
5
5´ 3´RNase H active
Plasma membrane
ATL1103
Cytoplasm
Nucleus
RNaseH
GHR
mRNA
DNA
Figure 1
Cartoon representation of ATL1103 and the mechanism of 
antisense inhibition. ATL1103 is a second-generation, 20-mer 
antisense oligonucleotide with a phosphorothioate backbone 
and 2′-O-methoxyethyl modiications of the terminal ive 
nucleotides at each end, which in combination increase its 
plasma half-life and afinity for the mRNA. Post-hybridisation 
RNase H degradation results in inhibition of GHR translation. 
GHR, growth hormone receptor.
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2. were 18–80 years of age, inclusive,
3. had acromegaly due to pituitary adenoma 
(microadenoma or macroadenoma) identiied by MRI,
4. had serum IGF-I level at screening >1.3 times the 
upper limit of normal (ULN),
5. had documented serum GH nadir levels >1 ng/mL at 
all test time points within the 2 h post oral glucose 
load for an oral glucose tolerance test (OGTT) (this 
could be historical),
6. were acromegaly treatment naïve or who had not 
taken other acromegaly medications for at least the 
following periods of time prior to IGF-I and GH 
screening tests: bromocriptine: 6 weeks; carbergoline: 
8  weeks; quinagolide: 8  weeks; octreotide 
(subcutaneous): 4  weeks; pegvisomant: 8  weeks; 
octreotide LAR: 4  months; 
lanreotide (all presentations): 4 months,
7. had a BMI ≥19 kg/m2,
8. had adequate venous access to allow collection of 
multiple blood samples during the study,
9. were female of non–child-bearing potential (i.e., 
either surgically sterilised or at least 1  year post-
menopausal), or, if of child-bearing potential, agreed 
to use two approved methods of contraception for 
the duration of the study and for 3  months after 
administration of the last dose of study drug, or were 
male and surgically sterilised or agreed to use an 
approved method of contraception for the duration 
of the study and for 3 months after administration of 
the last dose of study drug,
10. were willing and able to self-administer subcutaneous 
injections.
(Inclusion criteria 5, 6 and 9 were amended in protocol 
amendments during the study. For inclusion criterion 5, 
the requirement for GH after OGTT at screening was 
altered, as this could be historical. Inclusion criterion 6 
was amended to clarify that the washout periods detailed 
were minimum periods. For inclusion criterion 9, 
contraceptive requirements were clariied.)
Exclusion criteria
Patients who
1. had acromegaly due to reasons other than pituitary 
adenoma,
2. had a pituitary adenoma that was less than 3 mm 
distance from the optic chiasm,
3. had undergone pituitary surgery within the 3 months 
preceding the screening visit,
4. had received pituitary radiotherapy within the 1 year 
preceding the baseline visit,
5. had insulin-treated diabetes or had commenced a new 
hypoglycaemic drug for diabetes within the 2 months 
prior to screening,
6. had congestive heart failure, unstable angina, 
clinically signiicant cardiac arrhythmia, or a history 
of acute myocardial infarction within the 3 months 
preceding the baseline visit,
7. had abnormal hepatic function at screening deined 
any of the following parameters >2× ULN: aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), gamma glutamyl transferase (GGT), alkaline 
phosphatase (ALP), prothrombin time or total 
bilirubin,
8. had hepatitis B, hepatitis C or chronic liver disease,
9. were pregnant or lactating,
10. had known human immunodeiciency virus (HIV) 
(not tested speciically for this protocol) or history of 
Figure 2
Schematic representation of study 
protocol. The protocol entailed 
appropriate washout from any ongoing 
acromegaly medical therapy after which 
serum IGF-I had to be at least >1.3 times 
age-related ULN. All patients underwent 
pituitary MRI scans at baseline and 
completion of the study drug. An OGTT 
was undertaken at baseline (after 
washout) and again at the end of  
week 13. IGF-I, insulin-like growth factor 
1; OGTT, oral glucose tolerance test; ULN, 
upper limit of normal.
Patients currently on
other acromegaly drugs
Dosing Regimen 1
200 mg once weekly
13 patients
Dosing Regimen 2
200 mg twice weekly
13 patients
All Patients
Week –18 –4 –4 0 1 13 2114
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immunodeiciency that may have compromised their 
safety or affected results from this study,
11. had a history of alcohol or drug abuse in the 6-month 
period preceding the baseline visit.
Patients were recruited in 13 tertiary referral centres in 
Australia, France, Spain and the United Kingdom.
The study was approved by the NRES Committee East 
Midlands, Derby, UK; Bicêtre Hospital, France; Ethical 
Committee of Clinical Research, Hospital del al Santa 
Crue I Sant Pau, Barcelona, Spain and Royal Adelaide 
Human Research Ethics Committee, Adelaide, Australia. 
The study was registered as EudraCT 201200314730 
and ANZCTR 12611000854932. Patients gave written 
informed consent.
Procedures and study medication
Patients received either ATL1103 200 mg once or twice 
weekly 3 and 4 days apart for 13 weeks, with every patient 
receiving three doses in the irst week, administered 
every other day. Based on the tissue half-life of >4 weeks, 
experience from primate studies and data from the 
phase 1 study, additional ‘loading’ doses were administered 
in the irst week.
ATL1103 is formulated as a ‘ready-to-inject’ sterile 
solution at a concentration of 200 mg/mL, pH 7.4, 
in ‘Water for Injection’. Patients were taught to self-
administer ATL1103 subcutaneously. After completion of 
drug administration at the end of 13 weeks, patients were 
monitored, off all therapy for acromegaly, for a further 
8 weeks.
All patients underwent pituitary MRI scans at 
baseline and at week 13 (completion of the study drug), 
which were independently reviewed by two ‘blinded’ 
expert pituitary neurosurgeons. Tumour diameter 
changes of 2 mm or more in any one dimension or 
tumour volume changes of more than 20% were 
considered signiicant.
An OGTT with measurement of plasma glucose and 
serum GH was undertaken at baseline (after any drug 
washout) and again at the end of week 13. An adverse 
event (AE) assessment was undertaken at each of the 11 
study visits from baseline until study conclusion.
In addition to routine safety parameters, serum IGF-I, 
IGFBP3, ALS and GHBP were monitored. Ring size (fourth 
digit left hand) was measured using standard European-
sized jewellers’ ring sets, and patients completed a 
signs and symptoms score (SSS, maximum score 40) 
and the disease-generated ‘quality of life’ AcroQol. 
AcroQol comprises 22 questions divided into two 
main categories: physical and psychological function. 
The psychological category is further subdivided into 
appearance and personal relationships. Each question is 
scored out of 5, with a maximum score of 110 relecting 
best possible quality of life. The result is then converted 
to a percentage (8).
Randomisation and blinding
Permuted block randomisation (generated by a statistician 
and imported into the electronic case report form) was 
used to assign patients to either open-label, once- or 
twice-weekly ATL1003. Once initial data for a patient had 
been entered and the patient had fulilled all inclusion 
criteria, a randomisation number and treatment regimen 
were generated. Treatment allocation was not known to 
the operational personnel until this randomisation was 
performed.
Blocks of size four were used with no stratiication for 
the irst 24 patients. The list included an additional 24 
randomisation numbers using a block size of 2 (total 48) 
to allow for overage.
Assays
IGF-I, GH and IGFBP3
Serum IGF-I, GH and IGFBP3 were measured centrally 
by IDS-iSYS (Immunodiagnostic Systems, (IDS) Ltd., 
Boldon, England, UK) assays at the Endocrine Laboratory, 
Universität München (Munich, Germany). Recombinant 
standards (98/574 for GH and 02/254 for IGF-I) 
yielded interassay variability of 4.0–8.7% (IGF-I) and 
1.1–3.4% (GH) and sensitivity of 8.8 ng/mL (IGF-I) and 
0.04 ng/mL (GH) (9, 10). The limit of quantiication 
for IGFBP3 was 50 ng/mL and the intra- and interassay 
coeficients of variation (CVs) were 4.2% and 6.9% 
respectively (11).
ALS
Serum ALS levels were measured in duplicate by sandwich 
immunometric assay using monoclonal antibodies 
directed against speciic N- and C-terminal oligopeptides 
(12). A serum pool of healthy male volunteers was used 
for calibration and assigned 1000 U/L. The assay range is 
500–5000 U/L, and the intra- and inter-assay CVs were 
less than 9%. All samples from an individual subject were 
analysed in one run.
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GHBP
Serum GHBP levels were measured by a modiication of 
the ligand immunofunctional assay with an in-house 
monoclonal anti-GHBP antibody. Within-assay CVs were 
9.4% at 115 pmol/L and 6.1% at 1550 pmol/L. At the 
same concentrations, between-assay CVs were 8.5% and 
10.9% respectively. The lower limit of quantiication was 
69 pmol/L, and the linear range was 69–3500 pmol/L. All 
samples from an individual subject were analysed in one 
run (13).
Statistical analysis
The study was powered for within-group comparison of 
serum IGF-I (primary eficacy variable).
Based on a published pegvisomant study (3), a 
clinically meaningful reduction in baseline IGF-I was 
determined to be 27.5%, with a conservative estimate 
of S.D. of 30%. To achieve a level of signiicance of 0.05 
with a two-sided test, it was determined that a minimum 
sample size of 12 patients per treatment was required to 
achieve a power of at least 80%.
The planned eficacy analyses were within the 
intention-to-treat group. For the primary eficacy 
variable, the null hypothesis of no percentage change in 
fasting IGF-I levels from baseline to week 14 was tested 
for each treatment group with a (two-sided) one-sample 
t test and Wilcoxon signed-rank test. In addition, a pre-
speciied, though not powered for between-treatment 
groups, comparison was performed using a Wilcoxon 
rank-sum test (mathematically equivalent to Mann–
Whitney U test) for serum IGF-I 1 week after the last dose 
of study drug (week 14).
Baseline to week 14 testing for both cohorts was 
undertaken (Wilcoxon signed-rank test) for each of the 
secondary endpoints (the other components of the IGF 
ternary complex, namely IGFBP3 and ALS, plus circulating 
GH and GHBP, SSS, ring size and AcroQoL) and presented 
as median plus range.
A post hoc regression analysis of the relationship 
between change in IGF-I and dose/kg/week is reported 
with the associated 95% CI. Comparison of trapezoidal 
area under the curve for GH during the OGTTs is 
reported. Statistical signiicance is indicated by a P 
value <0.05.
Serum IGF-I data are expressed in mass units (ng/mL) 
and as a percentage of the upper limit of the age-related 
reference range.
Data Safety Monitoring Board
An independent Data Safety Monitoring Board (DSMB) 
was established prior to recruitment start, with an 
appropriate charter to direct decisions and monitor the 
trial safety results at intervals throughout the study 
and provided their recommendations as to whether the 
trial could continue as planned or whether there were 
any concerns. The DSMB comprised four individuals 
with appropriate experience in the areas of acromegaly, 
endocrine disorders, statistics and the conduct of clinical 
trials.
Results
Participants
Thirteen patients with active acromegaly (IGF-I >130% 
ULN at screening visit) (detailed in Fig.  3 and Table  1) 
were recruited into each study arm.
Eficacy
IGF-I
At baseline, the median serum IGF-I was 447 ng/mL 
(205–975) (2.5 × ULN) and 649 ng/mL (239–831) 
(2.75 × ULN) ng/mL, in the once- and twice-weekly groups 
respectively. Compared to baseline, at week 14, ATL1103 
N = 34
Number of patients
screened
N = 26
Number of patients
randomised
N = 13b
200 mg once weekly
Dosing Regimen 1
N = 12 (92.3%)
Completed study
N = 1 (7.7%)
Early withdrawal
Withdrawal of consent Withdrawal of consent
N = 12 (92.3%)
Completed study
N = 1 (7.7%)
Early withdrawal
N = 13b
200 mg twice weekly
Dosing Regimen 2
N = 8a
Number of patients
failed screening
Figure 3
Patient disposition. aFive patients failed screening as IGF-I was 
<130% ULN. bAlthough powered for 12 patients per arm, 13 
were included per arm since a commitment had been made to 
allow patients consented and ‘passing’ screening to receive 
study drug. IGF-I, insulin-like growth factor 1; ULN, upper limit 
of normal.
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at a dose of 200 mg twice weekly resulted in a median fall 
in serum IGF-I of 27.8% (range 4.4–49.8%, P = 0.0002), 
while no change was seen with once-weekly dosing. 
At week 14, the median fall in IGF-I was 25.8% greater 
with twice-weekly compared to once-weekly dosing 
(P = 0.0012). In the twice-weekly cohort, IGF-I levels were 
still declining at week 14, and at the end of the washout 
(week 21) remained lower than at baseline by a median of 
18.7% (P = 0.0005) (Figs 4 and 5).
In both dosing regimens, one patient had an IGF-I 
within the age-related reference range at the pre-deined 
endpoint of week 14. Normalisation of IGF-I at any time 
point was a pre-deined outcome measure and was met 
by one additional patient in the twice-weekly regimen 
(week 13).
Combining the data from the two dosing regimens, 
regression analysis of the percentage change in IGF-I 
levels vs dose/kg/week (median 2.88 (range 1.52–6.90)) 
demonstrated an estimated slope of regression of −8.27, 
indicative of a highly statistically signiicant (P = 0.0001) 
association between fall in IGF-I and the dose/kg/week 
(Fig. 6).
IGFBP3
In the twice-weekly cohort, at week 14, there was a 
median fall in serum IGFBP3 of 8.9% (range −29.2 to 
12.9%, P = 0.027) from baseline (median: 7005 ng/mL, 
range: 3396–9843). Once-weekly ATL1103 did not result 
in a signiicant change in serum IGBP3.
ALS
Compared to baseline, twice-weekly ATL1103 resulted in 
a median fall in ALS at week 14 of 16.7% (range −20.9 
to 34.9%, P = 0.017) from baseline (median: 1970 mU/mL, 
range: 945–2463). Once-weekly ATL1103 did not result in 
a signiicant change in serum ALS.
Table 1 Baseline characteristics of patients with acromegaly. Data are presented as median (range).
  200 mg ATL1103 once weekly 200 mg ATL1103 twice weekly
Number of patients 13 13
Age (years) 49 (26–72) 49 (32–80)
Sex (M/F) 5/8 6/7
Duration of disease* (years) 9.0 (1–24) 3 (<1–20)
Weight (kg) 90.6 (73.4–113.9) 83.2 (58–131.6)
Height (cm) 169 (154–194) 163 (148–197)
BMI (kg/m2) 31.8 (26.0–39.6) 29.4 (21.4–45.3)
Size of adenoma at diagnosis (no. (%))
 Micro (<10 mm) 2 (18) 2 (16.7)
 Macro (≥10 mm) 9 (81.8) 10 (83.3)
 Missing 2 1
Hypopituitarism at study entry (no. (%)) 4 (30.8) 4 (30.8)
Previous therapy (no. (%))
 Surgery 13 (100) 12 (92.3)
 Radiotherapy (all modalities) 6 (46.2) 5 (38.5)
 Dopamine agonist therapy 3 (23) 5 (38.5)
 Somatostatin analogue therapy 11 (84.6) 12 (92.3)
 Pegvisomant therapy 7 (53.8) 5 (38.5)
Serum growth hormone (ng/mL) 3.6 (0.4–60.6) 3.5 (1.5–9.4)
GH nadir (screening OGTT) (ng/mL) 2.5 (0.29–54.69) 2.4 (0.37–5.52)
Serum IGF-I (ng/mL) 447 (205–975) 642 (239–831)†
Serum GHBP (pM) 1179.0 (386–7637) 525.0 (<69–6434)‡
Serum IGFBP3 (ng/mL) 6589.0 (5162–9630) 7005.0 (3396–9843)
ALS (mU/mL) 1669.0 (1395–2829) 1970.0 (945–2463)
Ring size circumference (mm) 63.8 (57.5–81.4) 67.5 (53.7–78.9)
AcroQoL (global score) 58 (18–100) 71 (56–90)
SSS (calculated maximum score) 20.0 (1–36)§ 11 (7–30)
*Years from initial diagnosis to irst day of study; †baseline IGF-I missing for one patient, screening IGF-I value used for calculations; ‡n = 12, baseline 
GHBP missing for one patient; §n = 12, baseline SSS missing for one patient.
ALS, acid labile subunit; GH, growth hormone; GHBP, growth hormone–binding protein; IGFBP-3, insulin-like growth factor binding protein 3; OGTT, oral 
glucose tolerance test; IGF-I, insulin-like growth factor 1; SSS, signs and symptoms score.
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GH
In the twice-weekly cohort, median trapezoidal AUC for 
GH during the OGTT had increased by 46% (range −5.4 
to 419%, P = 0.001) at week 14 compared to baseline 
(471 ng·min/mL (79–867)). There was no change in GH 
levels in the once-weekly cohort (Fig. 7).
GHBP
There was a signiicant decline in serum GHBP levels in 
both cohorts at week 14. Twice-weekly ATL1103 resulted in 
a median decline of 48.8% (range −9.8 to 94.1%, P = 0.005) 
in GHBP from baseline (525 pmol/L (<69–6434), while a 
median fall of 23.6% (range −61.4 to 59.4%, P = 0.027) was 
seen in the once-weekly cohort (1179 pmol/L (386–7637), 
P = 0.027) and was maintained through to week 21. In 
the twice-weekly cohort, the median fall in serum GHBP 
at week 21 was 40.4% (range −94.1 to 6.1%, P = 0.008) 
compared to baseline (Fig. 8).
Ring size
There was a statistically signiicant decrease in ring 
size circumference (mm) from baseline to week 13 for 
regimen 2, with a median decrease of −1.25 mm (range 
−12.6 to 3.8, P = 0.039). Ring size was unchanged with 
once-weekly dosing.
Signs and symptoms score
There was no marked difference in either regimen in 
median SSS at baseline (20 (1–36) vs 11 (7–30)). The median 
percentage fall from baseline at week 14 was greater for twice-
weekly dosing 37.5% (range −185.7 to 91.7%) compared 
with 10.2% (range −33.3 to 83.3%) for once-weekly dosing, 
although the changes were not statistically signiicant.
AcroQol
The median absolute improvement in the physical 
dimension and global scores between baseline and 
Figure 4
Median percentage change from baseline in serum 
concentrations of IGF-I in patients with acromegaly. In the 
patients randomised to ATL1103 200 mg twice weekly, the 
median fall in serum IGF-I was 27.8% (P = 0.0002a) at the end 
of the treatment phase (week 14, 1 week after the last dose 
of study drug) compared to baseline (week 0). Between-
cohort analysis at week 14 demonstrated the median fall in 
serum IGF-I to be 25.8% (P = 0.0012) with twice-weekly 
compared to once-weekly dosing. In the twice-weekly cohort, 
IGF-I was still declining at week 14, and at week 21 remained 
lower than at baseline by a median of 18.7% (P = 0.0005b). 
Medians and interquartile ranges are plotted. IGF-I, insulin-
like growth factor 1.
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Figure 5
Percentage change in serum IGF-I levels from baseline to week 
14 in 26 patients treated with 200 mg ATL 1103 once or twice 
weekly. IGF-I, insulin-like growth factor-1.
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week 14 in the once-weekly cohort were 6.25 (range 0 to 
31.3, P = 0.002) and 3.4 (range −2.3 to 14.8, P = 0.0068) 
respectively, but these parameters did not change 
signiicantly with twice-weekly ATL1103.
In contrast, in the twice-weekly cohort, comparing 
baseline to week 14, the only signiicant inding was an 
improvement in the median absolute change for the 
appearance subsection of psychological dimension of 10.7 
(range −17.9 to 25.0, P = 0.035). There was no signiicant 
improvement in the once-weekly cohort.
Safety
ATL1103 was well tolerated with mild-to-moderate 
injection-site reactions (ISRs) being the most common 
treatment-emergent AE, affecting 85% of patients in both 
cohorts (Table 2). Four serious AEs (SAEs) were reported, of 
which three occurred in a single patient taking the once-
daily regimen (acute bronchitis, loss of consciousness 
while driving and cholecystitis) and one in a patient 
taking the twice-daily regimen (ear infection), but none 
were felt to be study drug related; both patients completed 
the 13  weeks of therapy. Two patients from one centre 
‘withdrew consent’ at completion of dosing (weeks 13 and 
14) with study drug and thus did not participate in the 
washout period through week 21.).
One patient in each regimen had low circulating 
platelet levels at a single time point (weeks 4 and 13, 86 
and 132 × 109/L respectively; normal range 150 × 109/L), 
but these resolved either spontaneously or after treatment 
end (week 13). Two patients had elevated liver enzymes 
judged clinically signiicant: one patient taking the once-
daily regimen had γ-glutamyltransferase, AST, ALT and ALP 
values above the normal limit (>ULN); one patient taking 
the twice-daily regimen had AST and ALT values >ULN. 
All effects on liver function were transient (Table 3).
The treatment-emergent AE (TEAE) proile was 
comparable for the two treatment groups (Table 2). Almost 
all patients experienced ISRs (mild and moderate), and 
‘mild’ lipohypertrophy, that subsequently, resolved was 
reported in two patients. There was a greater incidence 
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Figure 6
Scatterplot of the percentage change from baseline in IGF-I at 
week 14 by the allocated dose/kg/week. Combining the data 
from the two dosing regimens demonstrated a highly 
statistically signiicant (P = 0.0001) correlation with an 
estimated slope of regression of −8.27 (95% CI −11.97 to 
−4.56). IGF-I, insulin-like growth factor 1.
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Figure 7
Trapezoidal AUC for GH during OGTTs at baseline and week 
14. In the twice-weekly cohort, the median increase in AUC 
was 46% at week 14 compared to baseline (P = 0.001). There 
was no change in GH levels in the once-weekly cohort. AUC, 
area under the curve; GH, growth hormone; OGTT, oral 
glucose tolerance test.
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of headache in the once-weekly vs twice-weekly regimen 
(21 events and 5 events, respectively), but the number of 
patients who experienced headache was comparable (four 
patients in the once-daily regimen compared with three 
patients in the twice-daily regimen).
Radiologically signiicant tumour diameter changes 
(2 mm or more in any one dimension or tumour volume 
changes of more than 20%) were reported in three patients. 
Tumour volume increased in two patients (one in each 
dosing regimen, 5.7 × 7.3 × 19.1 vs 6.8 × 9.9 × 19.5 mm 
and 8.1 × 5.8 × 14.8 vs 8.1 × 7.2 × 16.2 mm) and reduced 
in one patient on twice-weekly dosing (6.2 × 10.4 × 4.9 vs 
2.6 × 5.7 × 4.1 mm). The changes were judged not to be 
clinically signiicant.
Discussion
The technology underpinning ASO therapy is rapidly 
advancing and has the potential to offer new therapeutic 
options across a broad spectrum of diseases. Disordered 
protein production or function is implicated in most 
pathological processes, and ‘gene silencing or activating’ 
by single-stranded ASOs against target RNA sequences 
is an attractive concept that permits greater speciicity 
than can be achieved with small molecules or antibodies 
(14). The synthetic structural modiications, such as the 
phosphorothioate backbone and 2′-O-methoxyethyl 
modiications, can be readily applied to whole classes of 
ASOs with only the nucleotide sequence being indication 
speciic. Encouraging studies of ASOs are being reported 
against many targets, but this is the irst report of the use 
of an ASO in endocrinology.
The data presented provide the ‘proof of concept’ 
that in patients with acromegaly, an ASO targeting 
the GHR can lower serum IGF-I and raise the prospect 
of a new and entirely novel therapy for acromegaly. 
Thirteen weeks of ATL1103 at a dose of 200 mg twice 
weekly lowered median serum IGF-I by 27.8%, with 
two (15%) of 13 patients achieving an IGF-I within the 
reference range. Serum IGF-I levels were still declining at 
week 14 and had not returned to baseline by the end of 
the 8-week (week 21) washout period (Fig. 4), suggesting 
that the duration of ATL1103 therapy was too short to 
see maximum beneit and that prolonged treatment at the 
same doses may result in a further decline in serum IGF-I. 
First-order drug kinetics indicate that approximately 
four to ive elimination half-lives are required to achieve 
steady-state plasma concentrations; since the tissue half-
life of ATL1103 is believed to be >4 weeks (15), this would 
suggest that between 16 and 20 weeks of treatment would 
be required for nadir IGF-I levels to be achieved.
In conjunction with the data indicating a relationship 
between the dose/kg/week and the fall in serum IGF-I, it 
seems probable that larger doses of ATL1103 administered 
for longer are likely to result in a greater fall in IGF-I and 
offer the prospect of ‘normalisation’ of IGF-I in a greater 
proportion of patients. Reassuringly, the decline in serum 
IGF-I with twice-weekly treatment was paralleled by falls 
in the other elements of the IGF ternary complex, namely 
IGFBP3 and ALS.
Circulating GHBP is the product of cleavage of the 
extracellular component of the GH receptor (16). In 
acromegaly, there is a negative correlation between serum 
GHBP concentrations and IGF-I and GH levels (17), 
such that GHBP concentrations are decreased in active 
acromegaly, and increase with conventional therapy. 
In contrast, the reduction in IGF-I caused by ATL1103 
therapy is associated with a signiicant decline in serum 
GHBP concentrations, which were still falling at week 14 
Figure 8
Median percentage change from baseline in serum 
concentrations of GHBP in patients with acromegaly. Twice-
weekly ATL1103 resulted in a median decline of 48.8% in 
GHBP (P = 0.005a) at week 14 (open symbols), while a median 
fall of 23.6% was seen in the once-weekly cohort (P = 0.027a). 
In the twice-weekly cohort, at week 21 the median fall in 
GHBP, compared to baseline, was 40.4% (P = 0.008b). Medians 
and interquartile ranges are plotted. GHBP, growth hormone–
binding protein.
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and had not returned to baseline by the end of washout 
at week 21. The fall in GHBP likely relects the ATL1103-
induced downregulation of GHR cell surface number, with 
a dose–response observed, as the fall was greater with the 
twice-weekly compared to once-weekly regimen, 23.6% 
and 48.8% respectively. The changes in GHBP emphasise 
the difference in action of ATL1103 and future studies 
with increased doses of ATL1103, and larger cohorts will 
permit exploration of the relationship between the change 
in serum IGF-I and circulating GHBP concentrations.
As with pegvisomant, the reduction in serum IGF-I 
with twice-weekly ATL1103 was associated with a 46% 
increase in serum GH levels assessed during an OGTT. 
Studies with pegvisomant have demonstrated that the 
increased GH secretion is a consequence of negative 
feedback in response to the fall in circulating IGF-I 
induced by blocking GH action (18).
It is encouraging that an improvement in the soft-
tissue manifestations of acromegaly, indicated by the 
reduction in ring size, was seen with twice-weekly therapy. 
The short duration of therapy and small cohort size means 
it should not be a surprise that the fall in IGF-I was not 
associated with an improvement in SSS and only very 
modest improvements in quality of life as measured by 
AcroQol. Studies in larger numbers of patients treated for 
longer are required to demonstrate the impact of ATL1103 
on well-being and quality of life.
Almost all patients, approximately 85%, experienced 
ISRs, but otherwise ATL1103 was generally well tolerated 
with no apparent drug-related SAEs. There were four 
SAEs, of which three occurred in one patient, and all 
were judged as unlikely to be drug related; both patients 
completed the 13 weeks of therapy (Table 2). ISRs are a 
recognised side effect of second-generation ASOs, were 
mild to moderate in severity (predominantly a mixture 
of erythema, pain and pruritus) and affected both cohorts 
equally. No patient withdrew from this study because of 
ISRs. This is a similar incidence of ISRs as reported in other 
studies: 90% of patients participating in a phase 2 study 
of mipomersen experienced mild-to-moderate ISRs (19). 
Table 2 Summary of treatment-emergent adverse events (safety set).*
 
 
200 mg once weekly 
(n = 13)
200 mg twice weekly 
(n = 13)
 
Total (N = 26)
n N % n N % n N %
TEAEs 98 11 84.6 88 11 84.6 186 22 84.6
Drug-related TEAEs† 33 6 46.2 24 8 61.5 57 14 53.8
Serious TEAEs 3 1 7.7 1 1 7.7 4 2 7.7
Severe drug-related TEAEs 0 0 0 0 0 0
Severe TEAEs 6 3 23.1 1 1 7.7 7 4 15.4
TEAEs leading to permanent discontinuation of study drug 0 0 0 0 0 0
Withdrawals 1§ 1§
Patients with ISR 11 84.6 11 84.6 22
 Mild 9 6  15
 Moderate 2 5 7
 Severe 0 0 0
Most frequent TEAEs with a >15% incidence
 Headache 21 4 30.8 5 3 23.1 26 7 26.9
 Fatigue 3 2 15.4 3 2 15.4 6 4 15.4
 Diarrhoea 3 2 15.4 2 2 15.4 5 4 15.4
 Constipation 2 2 15.4 2 2 15.4 4 4 15.4
 Dizziness 1 1 7.7 4 2 15.4 5 3 11.5
 Hyperhidrosis 1 1 7.7 4 2 15.4 5 3 11.5
 Rash 3 1 7.7 2 2 15.4 5 3 11.5
 Abdominal pain upper 1 1 7.7 2 2 15.4 3 3 11.5
 Nasopharyngitis 2 2 15.4 1 1 7.7 3 3 11.5
 Urinary tract infection 3 2 15.4 0 0 3 2 7.7
 Oropharyngeal pain 0 0 3 2 15.4 3 2 7.7
 Abdominal distension 0 0 2 2 15.4 2 2 7.7
 Abdominal pain 0 0 2 2 15.4 2 2 7.7
 Tracheitis 2 2 15.4 0 0 2 2 7.7
 Carpal tunnel syndrome 2 2 15.4 0 0 2 2 7.7
 Haematuria 2 2 15.4 0 0 2 2 7.7
 Lipohypertrophy 2 2 15.4 0 0 2 2 7.7
*Excludes ISRs; †drug related is deined as relationship to study drug = possible, probable, or deinite; §withdrew consent after last drug dose.
ISR, injection-site reaction; N, number of patients; n, number of events; %, percentage of patients; TEAE, treatment-emergent adverse event.
E
u
ro
p
e
a
n
 J
o
u
rn
a
l 
o
f 
E
n
d
o
cr
in
o
lo
g
y
179:2 107Clinical Study P J Trainer and others Antisense oligomer treatment 
for acromegaly
www.eje-online.org
The mechanism of oligonucleotide-induced ISR is yet to 
be fully elucidated, but skin biopsies in 9 of 32 subjects 
participating in a phase 1 study of mipomersen were 
consistent with leukocytoclastic vasculitis (e.g., iniltrating 
neutrophils, prominent nuclear dust, lymphocytes and 
eosinophils with local macrophage iniltration) (20). The 
lessons learned from the numerous other ASOs under 
clinical development will inform the management of ISRs 
in future studies of ATL1103. Transient changes in platelet 
count and liver function were encountered but were 
judged not to necessitate any change in therapy. Studies 
of greater length involving larger numbers of patients are 
required before any conclusions can be drawn about the 
safety proile of ATL1103.
There were no clinically signiicant changes in 
pituitary tumour size, but the short duration of treatment 
precludes meaningful conclusions about the long-term 
impact of ATL1103 on this parameter. Both the patients 
in whom tumour expansion of >2 mm was documented 
had discontinued somatostatin analogue therapy 
(one octreotide, one lanreotide) prior to commencing 
ATL1103, raising the possibility of rebound expansion 
from somatostatin analogue-induced tumour shrinkage. 
Reassuringly, the experience from more than 10-year use 
of pegvisomant is that GHR-targeted therapy does not 
induce growth of pituitary adenomas (21).
In summary, ATL1103 lowers IGF-I in acromegaly with 
biochemical changes consistent with downregulation of 
the GHR. As IGF-I was still declining at the end of the 
treatment period and with the knowledge that the dose/kg 
could be increased, ATL1103 has the potential to achieve 
disease control in a signiicant proportion of patients. 
Placebo-controlled studies of longer duration and using 
higher doses are needed to better assess the full potential 
of this novel treatment.
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